[1] |
Johnson NW, Jayasekara P, Amarasinghe AA . Squamous cell carcinoma and precursor lesions of the oral cavity: epidemiology and aetiology[J]. Periodontology 2000, 2011,57(1):19-37.
|
[2] |
Szklarczyk D, Morris JH, Cook H , et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible[J]. Nucleic Acids Res, 2017,45(Database issue):D362-D368.
|
[3] |
Okazaki T, Honjo T . The PD-1-PD-L pathway in immunological tolerance[J]. Trends Immunol, 2006,27(4):195-201.
|
[4] |
Valentini AM, Di Pinto F, Cariola F , et al. PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments[J]. Oncotarget, 2018,9(9):8584-8596.
|
[5] |
Wu P, Wu D, Li L , et al. PD-L1 and survival in solid tumors: a meta-analysis[J]. PLos One, 2015,10(6):e0131403.
|
[6] |
Lei ZG, Ren XH, Wang SS , et al. Immunocompromised and immunocompetent mouse models for head and neck squamous cell carcinoma[J]. Onco Targets Ther, 2016,9:545-555.
|
[7] |
Heineman TE, Widman A, Kuan EC , et al. The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer[J]. Laryngoscope Investig Otolaryngol, 2017,2(3):99-103.
|
[8] |
Ferris RL, Blumenschein G Jr, Fayette J , et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J]. New Eng J Med, 2016,375(19):1856-1867.
|
[9] |
Wowk ME, Trapani JA . Cytotoxic activity of the lymphocyte toxin granzyme B[J]. Microbes Infect, 2004,6(8):752-758.
|
[10] |
Du W, Leigh ND, Bian G , et al. Granzyme B contributes to the optimal graft-versus-tumor effect mediated by conventional CD4+T cells[J]. J Immunol Res Ther, 2016,1(1):22-28.
|
[11] |
Jie HB, Srivastava RM, Argiris A , et al. Increased PD-1+ and TIM-3+ TILs during cetuximab therapy inversely correlates with response in head and neck cancer patients[J]. Cancer Immunol Res, 2017,5(5):408-416.
|
[12] |
Chuang JY, Yang WH, Chen HT , et al. CCL5/CCR5 axis promotes the motility of human oral cancer cells[J]. J Cell Physiol, 2010,220(2):418-426.
|
[13] |
da Silva JM, Moreira Dos Santos TP, Sobral LM , et al. Relevance of CCL3/CCR5 axis in oral carcinogenesis[J]. Oncotarget, 2017,8(31):51024-51036.
|
[14] |
Chen KQ, Bao ZY, Tang P , et al. Chemokines in homeostasis and diseases[J]. Cellular and Molecular Immunology, 2018,15(4):324-334.
|
[15] |
Lai WY, Huang BT, Wang JW , et al. A novel PD-L1-targeting antagonistic DNA aptamer with antitumor effects[J]. Mol Ther Nucleic Acids, 2016,5(12):e397.
|
[16] |
De Waele J, Marcq E, Van Audenaerde JR , et al. Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade[J]. Oncoimmunol, 2017,7(3):e1407899
|